Westfuller Advisors LLC Purchases 831 Shares of Thermo Fisher Scientific Inc. $TMO

Westfuller Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 160.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,348 shares of the medical research company’s stock after purchasing an additional 831 shares during the period. Westfuller Advisors LLC’s holdings in Thermo Fisher Scientific were worth $654,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Delta Financial Advisors LLC bought a new position in Thermo Fisher Scientific in the third quarter worth about $776,000. Lockheed Martin Investment Management Co. raised its holdings in Thermo Fisher Scientific by 45.3% in the third quarter. Lockheed Martin Investment Management Co. now owns 11,160 shares of the medical research company’s stock worth $5,413,000 after purchasing an additional 3,480 shares in the last quarter. Hudson Value Partners LLC grew its holdings in Thermo Fisher Scientific by 14.6% in the third quarter. Hudson Value Partners LLC now owns 10,614 shares of the medical research company’s stock worth $5,148,000 after purchasing an additional 1,356 shares during the period. UNIVEST FINANCIAL Corp raised its stake in Thermo Fisher Scientific by 12.9% during the third quarter. UNIVEST FINANCIAL Corp now owns 35,515 shares of the medical research company’s stock valued at $17,226,000 after buying an additional 4,071 shares during the last quarter. Finally, Coign Capital Advisors LLC raised its holdings in Thermo Fisher Scientific by 9.9% in the third quarter. Coign Capital Advisors LLC now owns 1,362 shares of the medical research company’s stock worth $660,000 after buying an additional 123 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on TMO shares. Hsbc Global Res upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 1st. Morgan Stanley lifted their price objective on Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Citigroup upgraded Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and lifted their price target for the company from $580.00 to $660.00 in a report on Thursday, December 11th. Wells Fargo & Company increased their price objective on Thermo Fisher Scientific from $635.00 to $675.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $625.47.

Insider Buying and Selling

In related news, EVP Michael D. Shafer sold 10,725 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total value of $6,435,000.00. Following the sale, the executive vice president directly owned 18,731 shares in the company, valued at $11,238,600. The trade was a 36.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Frederick M. Lowery sold 6,913 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $597.68, for a total transaction of $4,131,761.84. Following the transaction, the executive vice president owned 14,367 shares in the company, valued at approximately $8,586,868.56. The trade was a 32.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 131,767 shares of company stock valued at $76,467,793 over the last ninety days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $625.42 on Friday. The stock has a market cap of $234.98 billion, a P/E ratio of 36.13, a PEG ratio of 4.21 and a beta of 0.91. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The company has a 50-day moving average price of $590.88 and a 200 day moving average price of $530.87.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The firm had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter last year, the company posted $5.28 EPS. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Investors of record on Monday, December 15th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend was Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is 9.94%.

Thermo Fisher Scientific announced that its board has initiated a stock repurchase plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.